glp 1 clinical pearls for Individualizing T2DM Therapy with SGLT2 Inhibitors and GLP-1 RAs Pharmacovigilance analysis of neurological adverse
Description
The two covered below are liraglutide and tirzepatide
[DOI] [PMC free article] [PubMed] [Google Scholar] 54.American Diabetes Association Professional Practice Committee, ElSayed NA, Aleppo G, et al
Third, retrospective observational studies have inherent limitations, including unmeasured or uncontrolled confounders and biases
OR #2: MOST individuals will be healthier after stopping medications
There is no scenario where stacking two GLP-1 agonists makes pharmacological sense, and no calculator can make an unsafe combination safe
